Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6P4Q7
UPID:
CNNM4_HUMAN
Alternative names:
Ancient conserved domain-containing protein 4; Cyclin-M4
Alternative UPACC:
Q6P4Q7; B7Z1U0; C7SQM3; C7SQM4; C7SQM5; Q53RE5; Q9H9G3; Q9HCI0; Q9NRN1
Background:
Metal transporter CNNM4, also known as Ancient conserved domain-containing protein 4 or Cyclin-M4, plays a crucial role in biomineralization and retinal function. It is a probable metal transporter, with its interaction with the metal ion chaperone COX11 indicating a significant role in sensory neuron functions.
Therapeutic significance:
CNNM4's association with Jalili syndrome, a condition marked by cone-rod dystrophy and amelogenesis imperfecta, underscores its therapeutic potential. Understanding the role of Metal transporter CNNM4 could open doors to potential therapeutic strategies for this syndrome.